The financing will support clinical trials, product development and team expansion as the business pursues international regulatory approvals.
"Our work in the US and the success of the trials we have run to date have demonstrated the potential of our technology and encouraged us to pursue other applications. With this financing and the backing of our investors we can accelerate our mission of delivering effective and non-invasive solutions for some of the most common and debilitating medical conditions."
The minority investment is backed by Hermes GPE and will drive customer-centric product innovation.
"We are delighted to have Newlands Capital onboard to help us continue our product led growth,putting the customer experience first in everything we do. The bespoke investment offered by Newlands and their 20 year plus technology investment experience is what we need at this point in the development of Capsule."
IQ Capital led the Series A financing to support the cybersecurity provider's continued growth.
"Cyber security has become increasingly important, more so with the global shift to remote working, especially for the SMB market that CyberSmart supports. CyberSmart has already achieved great success by identifying SMBs as a market segment that was underserved by the cyber security industry. The company has a strong product-market fit, is hitting targets well ahead of schedule, and has secured strategic partnerships to further market penetration within the UK and internationally. The team has been incredible to work with over the last year and demonstrated thought leadership and deep understanding of the needs of SMBs, enabling CyberSmart to provide automated, and simple to implement protection for firms with 1-20+ employees"
Par Equity led the Series A round to support technology development and commercial expansion.
"We are delighted to continue working with Par Equity who have been very supportive of our company and our vision. This investment will enable us to continue to develop and commercialise our cutting-edge technology that addresses a major unmet need in the development of novel therapies that can significantly reduce costs of care and improve patient outcomes for millions of people worldwide."
